HD-OPM Archive
Topics › Brain health & dementia

Two randomized trials of statins as Alzheimer's treatment were neutral

Louis Nervegna · Nov 01, 2026 · ♥ 6 reactions · 0 comments · original Facebook post
Brain health & dementiaStatins
↻ This is a repost. The main version (highest ranked) is Two RCTs found statins neither helped nor harmed Alzheimer's disease progression · Jun 23, 2025.
AI summary & key facts

Louis summarizes that two RCTs tested statins as a treatment for Alzheimer's disease, one with simvastatin and one with atorvastatin, and both were neutral. The simvastatin trial randomized 406 people with mild to moderate Alzheimer's to 20-40 mg daily or placebo for 18 months; lipids fell but cognitive decline did not change and there was no increase in adverse events.

(no text — see the shared post below)

Research cited

There have been two randomized controlled trials testing statins as a treatment for Alzheimer’s Disease.

One used simvastatin, and the other used atorvastatin.

Both trials showed a neutral result. The statins did not slow the progression of the disease, nor did they worsen it.

—— Simvastatin trial ——

Publication:

Paper · Neurology · 2011A randomized, double-blind, placebo-controlled trial of simvastatin to treat Alzheimer diseaseneurology.org

Quoted:

“This randomized, double-blind, placebo-controlled trial of simvastatin was conducted in individuals with mild to moderate AD and normal lipid levels. Participants were randomly assigned to receive simvastatin, 20 mg/day, for 6 weeks then 40 mg per day for the remainder of 18 months or identical placebo. The primary outcome was the rate of change in the Alzheimer's Disease Assessment Scale–cognitive portion (ADAS-Cog).”

“A total of 406 individuals were randomized: 204 to simvastatin and 202 to placebo. Simvastatin lowered lipid levels but had no effect on change in ADAS-Cog score or the secondary outcome measures. There was no evidence of increased adverse events with simvastatin treatment.”

—— Atorvastatin trial ——

Publication:

Paper · Neurology · 2010Randomized controlled trial of atorvastatin in mild to moderate Alzheimer disease: LEADe.Conclusion: In this large-scale randomized controlled trial evaluating statin therapy as a treatment for mild to moderate Alzheimer disease, atorvastatin was not associated with significant clinical benefit over 72 weeks. This treatment was generally well-tolerated without unexpected adverse events.neurology.org

Quoted:

“This was an international, multicenter, double-blind, randomized, parallel-group study. Subjects had mild to moderate probable AD (Mini-Mental State Examination score 13–25), were aged 50–90 years, and were taking donepezil 10 mg daily for ≥3 months prior to screening. Entry low-density lipoprotein cholesterol levels (LDL-C) were >95 and <195 mg/dL. Patients were randomized to atorvastatin 80 mg/day or placebo for 72 weeks followed by a double-blind, 8-week atorvastatin withdrawal phase. Coprimary endpoints were changes in cognition (Alzheimer's Disease Assessment Scale-Cognitive Subscale [ADAS-Cog]) and global function (Alzheimer's Disease Cooperative Study Clinical Global Impression of Change [ADCS-CGIC]) at 72 weeks.”

“A total of 640 patients were randomized in the study. There were no significant differences in the coprimary endpoints of ADAS-cog or ADCS-CGIC or the secondary endpoints. Atorvastatin was generally well-tolerated.”

————-

#statinsHD #dementiaHD #alzheimersHD #statinsdementiaHD #ldldementiaHD #atorvastatinHD #simvastatinHD

← newer: Cholesterol-lowering gene variants cut dementia risk 76-82% older: STAREE: atorvastatin cut major CV events 30% in adults 70+ w →